ATP Binding Cassette Subfamily D Member 1 (ABCD1) Antibody
357.5€ (100 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
ATP Binding Cassette Subfamily D Member 1 (ABCD1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx038301
tested applications
ELISA, WB, IHC
Description
Rabbit Polyclonal against the ABCD1 protein.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Target: ATP Binding Cassette Subfamily D Member 1 (ABCD1) Immunogen: Recombinant fragment corresponding to 560-737 AA of human ABCD1. |
| Host | Rabbit |
| Reactivity | Human |
| Assay Type | Concentration: Lyophilized form: Not applicable. After reconstitution: 1 mg/ml. |
| Recommended Dilution | ELISA: 1/20000 - 1/80000, WB: 1/500 - 1/2000, IHC: 1/100 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Observed MW | Observed MW: 83 kDa |
| Purification | Purified by Protein A/G column chromatography. |
| Size 1 | 100 µg |
| Size 2 | 1 mg |
| Form | Lyophilized |
| Tested Applications | ELISA, WB, IHC |
| Buffer | Prior to lyophilization: 0.02% NaN3. |
| Availability | Shipped within 7-15 working days. |
| Storage | Store at -20 °C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| NCBI Accession | NM_000033 |
| Alias | ABC42,ALD,ALDP,AMN,Adrenoleukodystrophy protein |
| Background | Antibody anti-ABCD1 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Descripción
ATP Binding Cassette Transporter D1 (ABCD1), part of the peroxisomal ABC transporter family, facilitates the import of very-long-chain fatty acids (VLCFAs) into peroxisomes for degradation. Mutations in the ABCD1 gene cause X-linked adrenoleukodystrophy (X-ALD), a neurodegenerative disorder characterized by the accumulation of VLCFAs in the central nervous system, adrenal glands, and plasma. ABCD1 dysfunction leads to demyelination, adrenal insufficiency, and progressive neurological decline. The protein is ubiquitously expressed, with high levels in tissues involved in lipid metabolism, including the liver, adrenal glands, and brain. Therapies targeting ABCD1, such as gene therapy and dietary interventions to reduce VLCFA levels, have shown promise in mitigating disease progression. Its essential role in lipid homeostasis highlights its broader relevance in metabolic and peroxisomal disorders.
Related Products
ABCD1 antibody
Probable transporter. The nucleotide-binding fold acts as an ATP-binding subunit with ATPase activity.
Ver ProductoABCD1 antibody
Probable transporter. The nucleotide-binding fold acts as an ATP-binding subunit with ATPase activity.
Ver ProductoABCD1 antibody
Probable transporter. The nucleotide-binding fold acts as an ATP-binding subunit with ATPase activity.
Ver Producto